Optimal two-stage designs based on restricted mean survival time for a single-arm study.

Optimal two-stage designs based on restricted mean survival time for a single-arm study.
复制标题

基于单臂研究的平均生存时间的最佳两阶段设计。

DOI:
10.1016/j.conctc.2021.100732
复制
发表时间:
2021-03
影响因子:
1.5
通讯作者:
Shan G
Shan G
中科院分区:
其他
文献类型:
--
作者:
Shan G

文献摘要

参考文献

被引文献

相似文献

在具有至事件发生时间结局的临床试验中,限制性平均生存时间是治疗效果与风险比的替代指标。目前的方法主要集中在单阶段设计。在这篇文章中,我们提出了最佳的两阶段设计的单臂研究与最小的预期样本量。我们比较了新的最优两阶段设计与现有的一阶段设计在预期样本量和预期总研究长度方面的性能。仿真结果表明,新的两阶段设计可以节省预期的样本量大幅相比,一阶段设计。我们使用一个非小细胞肺癌试验来说明所提出的设计的应用。当患者入组时间长于预先规定的随访时间时,建议使用拟议的最佳两阶段设计。
Restricted mean survival time is an alternative measure of treatment effect to hazard ratio in clinical trials with time-to-event outcome. The current methods have been focused on one-stage designs. In this article, we propose optimal two-stage designs for a single-arm study with the smallest expected sample size. We compare the performance of the new optimal two-stage designs with the existing one-stage design with regards to the expected sample size and the expected total study length. The simulation results indicate that the new two-stage designs can save the expected sample size substantially as compared to the one-stage design. We use a non-small cell lung cancer trial to illustrate the application of the proposed designs. The proposed optimal two-stage designs are recommended for use when time for patient accrual is longer than the pre-specified follow-up time.
DOI: 10.1080/10543406.2020.1730869
发表时间: 2020-02-28
影响因子: 1.1
作者:
Shan, Guogen
通讯作者: Shan, Guogen
DOI: 10.1177/0962280216650918
发表时间: 2018-04
影响因子: 2.3
作者:
Shan G
通讯作者: Shan G
DOI: 10.1080/07474946.2019.1611307
发表时间: 2019-04-03
影响因子: 0.8
作者:
Shan, Guogen;Zhang, Hua;Jiang, Tao
通讯作者: Jiang, Tao
DOI: 10.1002/pst.1846
发表时间: 2018-05-01
影响因子: 1.5
作者:
Huang, Bo;Kuan, Pei-Fen
通讯作者: Kuan, Pei-Fen
DOI: 10.7326/m14-1741
发表时间: 2015-07-21
影响因子: 39.2
作者:
Uno H;Wittes J;Fu H;Solomon SD;Claggett B;Tian L;Cai T;Pfeffer MA;Evans SR;Wei LJ
通讯作者: Wei LJ